Erythropoietin reduces anemia and transfusions
- 1 October 1999
- Vol. 86 (7) , 1362-1367
- https://doi.org/10.1002/(sici)1097-0142(19991001)86:7<1362::aid-cncr36>3.0.co;2-t
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatinCancer, 1997
- Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.Journal of Clinical Oncology, 1996
- Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapyCancer, 1995
- Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1995
- Taxol1 (Paclitaxel) in Patients with Metastatic Breast Carcinoma Who Have Failed Prior Chemotherapy: Interim Results of a Multinational StudyOncology, 1994
- Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot studyBritish Journal of Cancer, 1993
- Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapyGynecologic Oncology, 1992
- Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated AnemiaJNCI Journal of the National Cancer Institute, 1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989